Work

Randomized, multicenter phase II study of erlotinib (E) or E plus fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC).

Year: 2011

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2011.29.15_suppl.tps216

Authors: E. B. Garon, S. M. Dubinett, F. F. Kabbinavar, K. L. Reckamp, D. C. Marquez-Garban, L. Goodglick, S. Sharma, L. P. Stabile, J. Siegfried, R. J. Pietras

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2591559040

Cites:

Cited by: 5

Related to: 10